Johnson & Johnson (JNJ): FY25 Q1 earnings call, Apr 15, 2025

Tue, Apr 15Earnings callSpeaker-labelled transcriptJohnson & Johnson

No Kalshi or Polymarket word markets were listed for Johnson & Johnson’s Apr 15, 2025 earnings call (FY25 Q1). The transcript is searchable below (quotes of at most 25 words).

Updated

Transcript

quotes of at most 25 words

Speaker-labelled transcript · Source and credits · Used to count words; quotes of at most 25 words.

5 matches for “Carvykti”; 3 quoted, at least 25 words apart.

Joaquin Duatocompanyprepared

…is further proof of the impact of this medicine, which together with CARVYKTI, Talvey, and TECVAYLI, is changing the conversation from treating to progression to…

Joe Wolkcompanyqa

…the performance that we're seeing in the marketplace. I mean, look at CARVYKTI, I think, doubled sales year on year. So it's just a matter…

Jennifer Taubertcompanyqa

…And capacity expansion globally. And so, we have very firm conviction in CARVYKTI as a $5 billion-plus asset and really are rolling that out globally…

Agents: this page as TSV at /api/v1/appearances/johnson-and-johnson:2025-04-15:earnings_call · words: /api/v1/brief?appearance=johnson-and-johnson:2025-04-15:earnings_call · columnar JSON in #parrot-data · llms.txt · MCP